1,119
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis

ORCID Icon & ORCID Icon
Pages 9-13 | Received 16 Sep 2020, Accepted 14 Feb 2021, Published online: 08 Mar 2021

References

  • Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B, et al. Amyotrophic lateral sclerosis care and research in the USA during the COVID-19 pandemic: challenges and opportunities. Muscle Nerve. 2020;62:182–6.
  • Pinto S, Silani V, Chiò A, Calvo A, Salachas F, Camu W, et al. on behalf of the ENCALS and EAN expert panel. Amyotrophic Lateral Sclerosis and COVID-19: Recommendations to patients and caregivers. 2020. https://www.eanpages.org/2020/04/15/amyotrophic-lateral-sclerosis-and-covid-19-recommendations-to-patients-and-caregivers/
  • Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
  • Pinto S, de Carvalho M. Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegener Dis Manag. 2014;4:83–102.
  • De Carvalho M, Swash M, Pinto S. Diaphragmatic neurophysiology and respiratory markers in ALS. Front Neurol. 2019;10:143.
  • Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, et al. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:321–30.
  • Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review. CADTH Technol Overv. 2013;3:e3101.
  • McCormack MC, Kaminsky DA. Pulmonary function laboratories: advice regarding COVID-19. Available from: www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-laboratories.php
  • Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, et al. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:259–66.
  • Pinto S, Turkman A, Pinto A, Swash M, de Carvalho M. Predicting respiratory insufficiency in amyotrophic lateral sclerosis: the role of phrenic nerve studies. Clin Neurophysiol. 2009;120:941–6.
  • Miranda B, Pinto S, de Carvalho M. The impact of spasticity on diaphragm contraction: electrophysiological assessment. Clin Neurophysiol. 2018;129:1544–50.
  • Torrieri MC, Miranda B, Gromicho M, Pinto S, de Carvalho M. Reliability of phrenic nerve conduction study: in healthy controls and in patients with primary lateral sclerosis. Clin Neurophysiol 2020; 131(5):994–999.
  • Pinto S, de Carvalho M. Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis. Muscle Nerve. 2010;42:822–4.
  • Pinto S, Geraldes R, Vaz N, Pinto A, de Carvalho M. Changes of the phrenic nerve motor response in amyo-trophic lateral sclerosis: longitudinal study. Clin Neurophysiol. 2009;120:2082–5.
  • Pinto S, Pinto A, de Carvalho M. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123:2454–9.
  • Miranda B, Gromicho M, Pereira M, Pinto S, Swash M, de Carvalho M. Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. J Neurol. 2020;267:2123–9.
  • Matthews JN. Introduction to randomized controlled clinical trials. London: Arnold (Holder Headline Group); 2000.
  • Jenkins JAL, Sakamuri S, Katz JS, Forshew DA, Guion L, Moore D, et al. Phrenic nerve conduction studies as a biomarker of respiratory insufficiency in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:213–20.
  • van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333–41.
  • Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
  • Schmidt EP, Drachman DB, Wiener CM, Clawson L, Kimball R, Lechtzin N. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve. 2006;33:127–32.
  • Van Den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610–e1623.
  • Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:86–91.
  • Pinto S, de Carvalho M. Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:528–33.
  • Pinto S, de Carvalho M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol. 2019;28:109.
  • Christoph N, Burkhardt C, Alix J, Castro J, de Carvalho M, Gawel M, et al. Quality control of Motor Unit Number Index (MUNIX) measurements in 6 muscles in a single-subject “round-Robin” setup. PLoS One. 2016;11:e0153948.